High-grade Synovitis Associates with Clinical Markers and Response to Therapy in Chronic Inflammatory Arthritis: Analysis of a Synovial Biomarkers Prospective Cohort Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jan 26

PMID 38274811

Authors

Carlo Garaffoni

Marianna Tamussin

Ilaria Calciolari

Giovanni Lanza

Alessandra Bortoluzzi

Carlo Alberto Scire

Marcello Govoni

Ettore Silvagni

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory arthritis (IAs), such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), are characterized by the presence of chronic synovitis. The Krenn's synovitis score (KSS), a simple tool detectable by haematoxylin/eosin staining of synovial biopsy samples, allows the discrimination between high-grade and low-grade synovitis. The aim of this study was to identify the clinical associations of KSS and to evaluate the relationship between high-grade synovitis and treatment response in IA patients.

Methods: Clinical, laboratory and ultrasound data were retrieved from RA and PsA patients recruited in the prospective MATRIX cohort study. Inclusion criteria were age≥18 years, RA or PsA diagnosis, and presence of active disease with eligibility to start/modify therapy. Patients underwent ultrasound-guided synovial biopsy of one of the most involved joints before starting/modifying treatment according to treat-to-target strategy. The samples were analysed by an expert pathologist for KSS calculation. Univariable and multivariable logistic regression analyses were performed to evaluate the relationship between KSS and baseline variables. The association between KSS and treatment response at 24 weeks of follow-up was investigated in univariable logistic regression analysis.

Results: 53 patients, 34 RA and 19 PsA, completed 24 weeks of follow-up after synovial biopsy. Patients were either treatment naïve (N=6, 11%), csDMARDs-experienced (N=46, 87%) or b/tsDMARDs-experienced (N=20, 38%). Median KSS was 6.00 (Q1-Q3 4.00-7.00) in RA and 4.00 (3.00-6.00) in PsA (p=0.040), and inflammatory infiltrates score was significantly higher in RA than in PsA patients (median 3.00 vs 2.00, p=0.021). In multivariable analysis, synovial effusion in the biopsied joint (OR 9.26, 95%CI 2.12-53.91) and erythrocyte sedimentation rate (ESR) (OR 1.04, 95%CI 1.01-1.08) associated with high KSS. High-grade synovitis significantly associated with a higher probability of achieving DAS28 remission, ACR20/50 response, and Boolean2.0 remission, independently from diagnosis.

Conclusion: Several markers of pro-inflammatory pathways associated with the presence of high-grade synovitis, and patients with higher KSS shared a higher probability of treatment targets achievement in the follow up. The integration of a simple and feasible tool like KSS in the clinical and prognostic stratification of patients with IA might help in intercepting patients with a disease more prone to respond to available treatment paradigms.

Citing Articles

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.

Zabotti A, Aydin S, David P, Di Matteo A, McGonagle D Nat Rev Rheumatol. 2025; .

PMID: 40075177 DOI: 10.1038/s41584-025-01229-6.

References

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

Studenic P, Aletaha D, de Wit M, Stamm T, Alasti F, Lacaille D . American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2022; 75(1):15-22. PMC: 10092655. DOI: 10.1002/art.42347. View

Humby F, Durez P, Buch M, Lewis M, Rizvi H, Rivellese F . Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305-317. PMC: 7829614. DOI: 10.1016/S0140-6736(20)32341-2. View

Najm A, Goodyear C, McInnes I, Siebert S . Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nat Rev Rheumatol. 2023; 19(3):153-165. DOI: 10.1038/s41584-022-00874-5. View

Wells G, Becker J, Teng J, Dougados M, Schiff M, Smolen J . Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on.... Ann Rheum Dis. 2008; 68(6):954-60. PMC: 2674547. DOI: 10.1136/ard.2007.084459. View

Moll J, WRIGHT V . Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1):55-78. DOI: 10.1016/0049-0172(73)90035-8. View

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020; 80(1):31-35. PMC: 7788062. DOI: 10.1136/annrheumdis-2020-217344. View

Wakefield R, Balint P, Szkudlarek M, Filippucci E, Backhaus M, DAgostino M . Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005; 32(12):2485-7. View

10.

Alivernini S, Bruno D, Tolusso B, Bui L, Petricca L, Gigante M . Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Res Ther. 2019; 21(1):116. PMC: 6509792. DOI: 10.1186/s13075-019-1898-7. View

11.

Ciliento M, Venturelli V, Schettini N, Bertola R, Garaffoni C, Lanza G . Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis. Int J Mol Sci. 2023; 24(5). PMC: 10002880. DOI: 10.3390/ijms24055006. View

12.

Lliso-Ribera G, Humby F, Lewis M, Nerviani A, Mauro D, Rivellese F . Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis.... Ann Rheum Dis. 2019; 78(12):1642-1652. PMC: 6900253. DOI: 10.1136/annrheumdis-2019-215751. View

13.

Hosack T, Thomas T, Ravindran R, Uhlig H, Travis S, Buckley C . Inflammation across tissues: can shared cell biology help design smarter trials?. Nat Rev Rheumatol. 2023; 19(10):666-674. DOI: 10.1038/s41584-023-01007-2. View

14.

DAgostino M, Wakefield R, Berner-Hammer H, Vittecoq O, Filippou G, Balint P . Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Ann Rheum Dis. 2015; 75(10):1763-9. PMC: 5036216. DOI: 10.1136/annrheumdis-2015-207709. View

15.

Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak P, Canete J . Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2011; 64(1):99-109. DOI: 10.1002/art.33396. View

16.

Humby F, Lewis M, Ramamoorthi N, Hackney J, Barnes M, Bombardieri M . Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis. 2019; 78(6):761-772. PMC: 6579551. DOI: 10.1136/annrheumdis-2018-214539. View

17.

Rivellese F, Pitzalis C . Cellular and molecular diversity in Rheumatoid Arthritis. Semin Immunol. 2022; 58:101519. DOI: 10.1016/j.smim.2021.101519. View

18.

Smolen J, Landewe R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82(1):3-18. DOI: 10.1136/ard-2022-223356. View

19.

Generali E, Scire C, Favalli E, Selmi C . Biomarkers in psoriatic arthritis: a systematic literature review. Expert Rev Clin Immunol. 2016; 12(6):651-60. DOI: 10.1586/1744666X.2016.1147954. View

20.

van de Sande M, Gerlag D, Lodde B, van Baarsen L, Alivernini S, Codullo V . Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis. 2010; 70(3):423-7. DOI: 10.1136/ard.2010.139550. View